Key Details
Price
$2.99Annual Revenue
$33.88 MAnnual EPS
-$2.02Annual ROE
-59.14%Beta
0.50Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 02, 2022Analyst ratings
Recent major analysts updates
Screeners with CASI included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases.
BEIJING , Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C.
BEIJING , Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals.
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
BEIJING , July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link: https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm About CASI Pharmaceuticals CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world.
BEIJING , July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8 th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive.
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
FAQ
- What is the primary business of CASI Pharmaceuticals?
- What is the ticker symbol for CASI Pharmaceuticals?
- Does CASI Pharmaceuticals pay dividends?
- What sector is CASI Pharmaceuticals in?
- What industry is CASI Pharmaceuticals in?
- What country is CASI Pharmaceuticals based in?
- When did CASI Pharmaceuticals go public?
- Is CASI Pharmaceuticals in the S&P 500?
- Is CASI Pharmaceuticals in the NASDAQ 100?
- Is CASI Pharmaceuticals in the Dow Jones?
- When was CASI Pharmaceuticals's last earnings report?
- When does CASI Pharmaceuticals report earnings?
- Should I buy CASI Pharmaceuticals stock now?